Aragon Pharmaceuticals, Inc.
Records under this name other than the patents Aragon Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 37 patents it holds.
Showing 1 to 8 of 8 · Back to Aragon Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,285,948 | Anticancer Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 10,023,556 | Androgen Receptor Modulators and Uses Thereof Lapsed on the fee record Ended Jul 17, 2026 · High confidence | Lapsed on the fee record | Ended Jul 17, 2026 | High confidence |
| US 9,617,602 | Methods and compositions for determining resistance to androgen receptor therapy Lapsed on the fee record Ended Apr 11, 2025 · USPTO record | Lapsed on the fee record | Ended Apr 11, 2025 | USPTO record |
| US 9,481,664 | Androgen Receptor Modulators and Uses Thereof Lapsed on the fee record Ended Nov 1, 2024 · High confidence | Lapsed on the fee record | Ended Nov 1, 2024 | High confidence |
| US 9,108,944 | Androgen Receptor Modulators and Uses Thereof Lapsed on the fee record Ended Aug 18, 2023 · High confidence | Lapsed on the fee record | Ended Aug 18, 2023 | High confidence |
| US 10,052,314 | Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate Cancer Surrendered on reissue Surrendered on reissue Jan 3, 2023 · Low confidence | Surrendered on reissue | Surrendered on reissue Jan 3, 2023 | Low confidence |
| US 8,853,423 | Indane estrogen receptor modulators and uses thereof Lapsed on the fee record Ended Oct 7, 2022 · USPTO record | Lapsed on the fee record | Ended Oct 7, 2022 | USPTO record |
| US 9,855,270 | Methods and Compositions for Modulating Estrogen Receptor Mutants Formerly held Lapsed on the fee record Ended Jan 2, 2022 · Medium confidence | Lapsed on the fee record | Ended Jan 2, 2022 | Medium confidence |